John Warden Jr Biovista Talks About How Their Company Finds New Uses for Existing Drugs On the Market and Studies Side Effects BioPharm America 2011
This is a company that certainly provides a very needed process, finding side effect that sometimes end up being another form of treatment or therapy for existing
drugs. The company uses a software platform for some very extensive research. The company started working with the FDA in predicting adverse effects and has evolved into a company that repositions drugs.
They study compounds and find correlations by looking through pub med data. They take a drug that already has FDA approval and find a beneficial side effect that in many instances becomes a drug that could be prescribed for another therapy.
Pfizer and Novartis are a couple of their current clients. You can visit the website and find out more about some of their current projects and processes.
Micro-Cap Review Latest Issue
News from

Elite Traders Group Issues Four New Micro-Cap Research Reports on FCCN, MDNT, DOMK, and UOMO
Questfire Energy Corp. Announces Closing of Purchase of Oil and Gas Assets
Spring Value Investing Congress to Feature Rising Stars of Hedge Fund Industry
Nuvilex Inc.'s Medical Marijuana Segment Benefits From Recent Trends in Cancer Treatment
Questfire Energy Corp. Announces Year End 2012 Financial Results and Files Its NI 51-101 Disclosure
OTCBB Journal Where Savvy Traders Get the Hottest Due Diligence Issues New Micro-Cap Stock Report
Nuvilex Inc. and Other Small Cap Oncology Stocks on Fire Leading Up to ASCO Meeting
Small-Cap Specialists Is Offering Insights and Full Research Reports on Micro-Cap Stocks With Increasing Liquidity
Canadian Financing Bulletin (CFB) reports CDN $51.3m in proposed and $770.2m closed financings for the week of April 15-April 19.
Goldman Small Cap Research Issues Research Report on ARX Gold Corporation
http://www.marketwire.comSNNLiveTV Commercial
Cavaet Emptor or Buyer Beware by SNN Inc. CEO Sheldon “Shelly” Kraft
Check out the book "Caveat Emptor" written by CEO Sheldon Kraft, click on the image to view a preview and the full book can be purchased for $15.95.
There are some best practices and good hints on what to look out for in today’s volatile markets.




